Artificial intelligence (AI) can improve the diagnostic accuracy of skin cancer when combined with human clinical checks says a new study published in the journal Nature Medicine. The researchers analyzed whether a 'real world' collaborative approach incorporating clinicians aided by AI, enhanced the accuracy of clinical decision making related to skin cancer.

Monika Janda, author of the paper, said, in a statement, "This is important because AI decision support has slowly started to infiltrate healthcare settings, and yet few studies have tested its performance in the real world settings or how clinicians interact with it,"

Training And Testing An Algorithm

For the findings, the researchers trained and tested an artificial convolutional neural network to analyze pigmented skin lesions, and compared the findings to human evaluations on three types of AI-based decision support.

Artificial Intelligence
Representational Picture Pixabay

The study found that the highest diagnostic accuracy was achieved when crowd wisdom and AI predictions were combined, suggesting human-AI and crowd-AI collaborations were preferable to individual experts or AI alone.

Inexperienced evaluators gained the highest benefit from AI decision support and expert evaluators confident in skin cancer diagnosis achieved modest or no benefit, the researchers said. These findings indicated a combined AI-human approach to skin cancer diagnosis may be the most relevant for clinicians in the future.

Simplicity of AI Can Aid clinicians

Although AI diagnostic software has demonstrated expert-level accuracy in several image-based medical studies, researchers have remained unclear on whether its use improved clinical practice.

"Our study found that good quality AI support was useful to clinicians but needed to be simple, and in accordance with a given task," Janda said. "For clinicians of the future, this means that AI-based screening and diagnosis might soon be available to support them on a daily basis," Janda added.

Implementation of any AI software needs extensive testing to understand the impact it has on clinical decision making, the study noted.

(With inputs from agencies)